Implication of Bioelectronic Principle in Cancer Therapy : Treatment of Cancer Patients by Methylglyoxal—Based Formulation by Ray, Manju et al.
Indian J. Phys. 75B (2), 73-77 (2001)
U P  Ban intemationaJ jo u n al
Implication of the bioelectronic principle in cancer therapy : treatment 
of cancer patients by methylglyoxal-based formulation
Manju Ray'*, Swapna Ghosh', Maiioj Kar ,^ Santajit Datta^  ^and Subhankar Ray^
‘Deparlinent of Biological Chemistry, Indian Association for the Cultivation ol Science, Calcutta-700 032, India
E-mail ; bcmr@mahendra.iacs.res.in
‘Department of Biophysics Molecular Biology and Genetics, University College of Science, University of Calcutta, Calcutta-700 009, India
^L4/3 Regent Estate, Calcutta-700 092, India
^Department of Biochemistry, University College of Science, University of Calcutta, Calcutta-700 019, India 
R ece ived  J 9 M arch 2001, accep ted  20  M arch  2001
Abstract : Based on our previous in v itro  studies with human cells and m  vivo  studies with animals wo had developed an anticanoer 
formulation with methylglyoxal as the lead ingredient. This formulation has a tumoricidal effect by inhibiting specifically m cancerous cells, the 
elecU-on flow and the transfer of reducing equivalent necessary for the production of adenosme-5'-triphosphate (A1T), the cellular energy currency. 
By keeping this remarkable property in mind, we had treated 24 patients sutfenng from different types of malignancy (mostly in very advanced 
stage of the disease) with this methylglyoxal-ba.sed formulation. The results indicate a dramatic positive effect on the patients Out of the 24 
patients, 11 are in excellent physical condition, the condition of 5 patients can be considered .stable. The rest had either opted out from the 
treatment or died during the course of study These results strongly sugge.st that this fonnulation is by far more superior than other present forms 
of treatment agamsl cancer. It is imperative that this formulation be widely used in treating cancer patients, as well as to attempt the improvement 
of Its efficacy.
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1. Introduction
As early as 1958, the anticancer property of ketoaldehydes 
(such as methylglyoxal) and their derivatives were first, 
studied and effective response was obtained [1], Szent- 
Gybrgyi and his collaborators in their pioneering work on 
(he biological role of methylglyoxal had put forward strong 
evidences for the anticancer and growth inhibitory effect of 
methylglyoxal [2], It had been suggested that the anticancer 
property of methylglyoxal is due to its growth inhibitoiy 
effect. Szent-OyOrgyi had also suggested that proteins could 
act as electronic conductors and also pointed out the 
relationship of the loss of this properties with cancer. 
Moreover, the difference between normal differentiated cells 
and cancerous cells'could be due to the deficiency of certain 




Egytid and Szent-Gydrgyi showed that methylglyoxal 
c6uld completely inhibit the tumor development in mice. 
When methylglyoxal was injected into mice along with 
sarcoma 180 cells, no tumor developed and the mice 
remained completely healthy [3]. At the same time, Apple 
and Greenberg with their remarkable experiments showed 
that methylglyoxal significantly inhibited tumor growth and 
in some cases produced indefinite survivors among mice 
bearing leukemia, lymphosarcoma, adenocardnoma, sarcoma 
180 and other varieties of tumors at daily dose level of 
approximately 80 mg/kg of body weight. Single dose of 
about 223 mg/kg of body weight significantly inhibited 
advanced leukemia and produced indefinite survivors among 
mice bearing either lymphosarcoma or carcinoma [4,5], 
Similar therapeutic activity of methylglyoxal towards 
cancer bearing animals had also been obtained by other
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in v e s t ig a to rs  [6 ]. M o re o v e r , c a rc in o s ta t ic  a c t iv i ty  o f  
m e th y lg ly o x a i h ad  been  d e m o n s tra te d  c o n v in c in g ly  in in 
vitro e x p e rim e n ts  w ith  w id e  v a rie ty  o f  c a n c e ro u s  ce lls  
o b ta in ed  from  an im a ls  ( [ 6 ], fo r a re v ie w  R e f  [7 ]). F low ever, 
it is to  be n o ted  th a t a lm o s t a ll th e  a b o v e -m e n tio n e d  s tu d ie s  
had  b een  d o n e  w ith  an im a l sy s tem s  an d  p ra c tic a lly  n o  
s tu d ies  h ad  been  c o n d u c te d  w ith  h u m a n  m a te ria ls .
B ut su b se q u e n t e x p e rim e n ts  from  o u r la b o ra to ry  h ad  
c le a rly  d e m o n s tra te d  th a t m e th y lg ly o x a i is tu m o ric id a l [8 ]. 
It h ad  b een  o b se rv e d  w ith  in vitro s tu d y  th a t m e th y lg ly o x a i 
in h ib its  b o th  m ito c h o n d r ia l re sp ira tio n  an d  g ly c o ly s is  o f  
b o th  h u m a n  a n d  a n im a l m a lig n a n t tis su e s  an d  ce lls  [9 ,10 ]. 
M e th y lg ly o x a i in h ib its  sp e c if ic a lly  in m a lig n a n t ce lls  th e  
e lec tro n  flo w  th ro u g h  c o m p le x  I o f  th e  m ito c h o n d r ia l 
re sp ira to ry  ch a in  an d  a lso  th e  tra n s fe r  o f  re d u c in g  e q u iv a le n t 
n ec e ssa ry  fo r  th e  g e n e ra tio n  o f  A T P , th e  e n e rg y  c u rre n c y  
o f  liv in g  ce lls  [8 - 1 2 ] .  A s a c o n se q u e n c e  o f  in h ib itio n  o f  
m ito c h o n d r ia l re sp ira tio n  a n d  g ly c o ly s is , th e  A T P  level o f  
th ese  ce lls  a re  c r itic a lly  re d u c e d , re n d e r in g  th e m  n o n - 
v iab le  [9 ,1 0 ]. It h a s  a lso  b een  o b se rv e d  th a t a sc o rb ic  a c id  
s ig n ifican tly  au g m e n te d  the  tu m o rica l e ffec t o f  m e th y lg ly o x a i
[8 ]. O n  th e  o th e r  h a n d , u n d e r  id e n tic a l e x p e r im e n ta l 
c o n d itio n s , m e th y lg ly o x a i h ad  n o  e ffe c t on  th e  re sp ira tio n  
a n d  g ly c o ly s is  o f  n o rm a l (n o n m a lig n a n t)  tissu es  an d  ce lls  
[8 , 1 0 ].
B y  u s in g  b o th  in vitro an d  in vivo e x p e rim e n ts , the  re su lts  
o b ta in e d  fro m  d i f f e r e n t  s tu d ie s  a s  d e s c r ib e d  a b o v e , 
c o n v in c in g ly  d e m o n s tra te d  th a t m e th y lg ly o x a i is a p o te n t 
a n tic a n c e r  ag e n t. M e th y lg ly o x a i ac ts  se le c tiv e ly  a g a in s t 
m a lig n a n t ce lls , sp a r in g  th e  n o rm a l ce lls . Its e ffe c t can  b e  
s ig n if ic a n tly  a u g m e n te d  w ith  n a tu ra l c o m p o u n d (s ) , a sc o rb ic  
a c id  an d  o th e r  v ita m in s . M o re o v e r, m e th y lg ly o x a i is w ell 
to le ra te d  by  b o th  n o rm a l a n d  tu m o r  b e a rin g  a n im a ls , w h ich  
is in sh a rp  c o n tra s t to  th e  p ro p e r tie s  o f  o th e r  a n tic a n c e r  d ru g s  
n o w  w id e ly  u sed  in th e  tre a tm e n t o f  c a n c e r  p a tien ts . D esp ite  
a ll th e se  re su lts , it is v e ry  su rp r is in g  an d  u n fo r tu n a te , th a t 
n e ith e r  th e  p o te n tia lity  o f  m e th y lg ly o x a i as an  a n tic a n c e r  
d ru g  h ad  b e e n  se r io u s ly  in v e s tig a te d , n o r  its h u m a n  tr ia l h a d  
b een  in itia ted .
H o w e v e r, w e  h a v e  d e v e lo p e d  an  a n tic a n c e r  fo rm u la tio n  
w ith  m e th y lg ly o x a i as th e  lead  in g re d ie n t a n d  h av e  te s te d  its 
p o te n tia l to  tre a t c a n c e r  p a tie n ts  a n d  h av e  o b ta in e d  v e ry  
e n c o u ra g in g  re su lts . T h e se  p a tie n ts  w e re  su ffe r in g  fro m  
d if fe re n t ty p e s  o f  c a n c e r  a n d  m o s tly  w e re  in v e ry  a d v a n c e d  
s tag e  o f  th e  d isea se . A lm o s t a ll th e  p a tie n ts  w h o  h a d  re c e iv e d  
o u r  tre a tm e n t h a d  sh o w n  m a rk e d  im p ro v e m e n t in th e ir  
c o n d itio n s . B io c h e m ic a l a n d  o th e r  re le v a n t te s ts  w e re  d o n e , 
p r io r  to , d u rin g  a n d  a fte r  th e  tre a tm e n t. T h e  re su lts  o f  th e se  
te s ts  h ad  a lso  sh o w n  th a t th e  d if fe re n t p a ra m e te rs  in d ic a tin g  
th e  p a tie n ts  c o n d itio n s  h av e  co m e  to  a lm o s t n o rm a l leve l 
a f te r  th e  tre a tm e n t.
T h e  p re se n t p a p e r  d e sc r ib e s  th e  c o m p o s itio n  o f  th e  
fo rm u la t io n , its d o se  re g im e n  an d  tre a tm e n t s c h e d u le ,
c o n d i t io n s  o f  th e  p a t i e n t s  a n d  th e  r e s u l t s  o f  th e  
tre a tm e n t.
2. M a te r ia l s  a n d  m e th o d s
2. /. Patients :
T o ta l 24  p a tie n ts , b o th  m a le  an d  fe m a le  in th e  a g e  g ro u p  o f  
3 2 -7 8  y rs  re c e iv e d  th e  tre a tm e n t w ith  th e  p re se n t fo rm u la tio n  
(see  b e lo w ). T h e y  w e re  in d u c te d  fo r  th e  tr ia l fro m  Ja n u a ry  
to  Ju n e  2 0 0 0 . T h e  p a tie n ts  h a d  d if fe re n t ty p e s  o f  m a lig n a n c y  
c o n firm e d  by  b io p sy  a n d  in m o s t o f  th e  c a se s  m e ta s ta tic  
c a rc in o m a . A  few  o f  th e  p a tie n ts  h a d  re c e iv e d  n o  p rio r 
tre a tm e n t; o th e rs  h a d  re c e iv e d  tre a tm e n t o f  su rg e ry  a n d /o r  
ra d io th e ra p y  a n d /o r  c o n v e n tio n a l c h e m o th e ra p y ; b u t a lm o st 
all h ad  n o  im p ro v e m e n ts . T h e ir  c o n d it io n s  w o rse n e d  and 
th e re  w e re  m a n y  re la p se d  cases .
A ll th e  p a tie n ts  g a v e  in fo rm e d  c o n se n t to  p a r t ic ip a te  in 
th e  tre a tm e n t by  th e  p re s e n t fo rm u la tio n , th e  p ro to c o l o f  
w h ic h  h a d  b een  a p p ro v e d  by  th e  In s ti tu tio n a l E th ica l 
C o m m itte e  o f  In d ian  A sso c ia tio n  fo r  th e  C u lt iv a t io n  o f  
S c ie n c e . T h e  D ru g  C o n tro l le r  G e n e ra l ( In d ia )  h a d  a lso  
in d ic a te d  n o  o b je c tio n  in th e  s tu d y .
2 .2 .  Composilion and treatm ent schedule o f  the 
formulation
A  sto ck  so lu tio n  o f  0 .4 - 0 .4 5  M m e th y lg ly o x a i is e sse n tia lly  
th e  m a in  c o m p o n e n t o f  th e  p re s e n t fo rm u la tio n . E a c h  adu lt 
p a tie n t re c e iv e d  o ra l ly  a t a  tim e  1 0 - 1 2  m l o f  0 .4 - 0 .4 5  M 
m e th y lg ly o x a i d ilu te d  in 5 0 - 7 0  m l o f  w a te r , fo llo w e d  by 
ta b le t o f  c h e w a b le  v ita m in  C  c o n ta in in g  4 0 0  m g  o f  asco rb ic  
ac id . T h e  p a tie n t re c e iv e d  th is  tr e a tm e n t 4  t im e s /d a y  at 
re g u la r  in te rv a l. T h is  is e q u iv a le n t to  th e  in g e s tio n  o f 
2 0 - 2 5  m g  m e th y lg ly o x a l/k g  o f  b o d y  w t./d a y . E ach  p a tien t 
a lso  re c e iv e d  o ra lly  a  m ix tu re  o f  th e  fo l lo w in g  v itam in s  
tw ic e  a d ay  : B i 5 m g , B 2 5 m g , B 6 2 .5  m g , B 12 5 m e g  and 
B 5 7 .5  m g . T h is  tr e a tm e n t w a s  c o n tin u e d  fo r s ix  co n se c u tiv e  
d ay s . In  so m e  ca se s , th e re  w a s  n o  tre a tm e n t fo r  1 o r  2  days 
b e fo re  a n o th e r  s ix  d a y s  o f  tre a tm e n t in a  s im ila r  fa sh io n  
b e g a n . In  o th e r  c a se s  th e  tr e a tm e n t c o n tin u e d  w ith o u t any 
in te rru p tio n .
T h e  a b o v e -m e n tio n e d  sc h e d u le  o f  t r e a tm e n t c o n tin u e d  
fo r  8 - 1 0  w e e k s . T h e re a f te r  th e  a m o u n t o f  m e th y lg ly o x a i 
in g e s te d  w as  re d u c e d  to  1 4 - 1 6  m g / k g /d a y  w h ic h  w as 
d iv id e d  in 3 d o se s  in th e  d ilu tio n  a s  m e n tio n e d  a b o v e . A fter 
e a c h  in g e s tio n  o f  m e th y lg ly o x a i, th e  p a tie n t re c e iv e d  one 
ta b le t  o f  c h e w a b le  v ita m in  C  c o rre s p o n d in g  to  4 0 0  m g  o f 
a s c o rb ic  a c id . T h e  s u p p le m e n ta t io n  o f  o th e r  v itam in s  
c o n tin u e d  a s  b e fo re . T h is  s c h e d u le  c o n tin u e d  fo r  an o th er 
15 w e e k s . D e p e n d in g  o n  th e  c o n d it io n  o f  th e  p a tie n ts , the 
tre a tm e n t w a s  e ith e r  d is c o n tin u e d  o r  c o n tin u e d  w ith  fu rther 
low  d o se  o f  th e  p re s e n t fo rm u la tio n .
2 .3 . Assessment o f response to treatment :
A p p ro p r ia te  p h y s ic a l a n d  b io c h e m ic a l e x a m in a tio n  a s  well 
a s  g e n e ra l w e ll b e in g  o f  th e  p a tie n ts  d id  a s s e s sm e n t o f
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response to  th e  tre a tm e n t. B io c h e m ic a l, p a th o lo g ic a l an d  
o ther p h y s ic a l te s ts  o f  th e  p a tie n ts  w e re  d o n e  in a p p ro v e d  
clin ical la b o ra to r ie s .
2 4 Materials :
M e ih y lg ly o x a l  ( p y r u v a l d e h y d e )  w a s  o b ta in e d  f ro m  
Sigm a C h e m ic a l C o . St. L o u is , M O , U S A . A sc o rb ic  ac id  
(v itam in  C ) a n d  o th e r  v ita m in s  w e re  p ro d u c ts  o f  d if fe re n t 
p h a rm aceu tica l c o m p a n ie s  an d  o b ta in e d  fro m  lo ca l m e d ic in e  
shops.
3 . R e su lts
The resu lts  o f  th e  tre a tm e n t o f  24  p a tien ts  w ith  th e  fo rm u la tio n  
and sc h e d u le  o f  t r e a tm e n t a s  d e sc r ib e d  in th e  m a te r ia ls  an d  
m ethods a re  su m m a ris e d  in T a b le  1. T h e  s tu d y  w as  m ad e  
with p a tie n ts , s u f fe r in g  fro m  v a rio u s  ty p e s  o f  m a lig n a n c ie s  
affec ting  d if fe re n t o rg a n s  o f  th e  b o d y . T h e  c o n d itio n s  o f  th e  
patien ts d e sc r ib e d  h e re in  a re  a t th e  tim e  o f  su b m ittin g  th e  
presen t m a n u s c r ip t fo r  p u b lic a tio n . It a p p e a rs  fro m  th e  re su lt 
that 11 o f  th e  2 4  p a tie n ts  tr e a te d  a re  in 'e x c e l le n t ' p h y s ic a l 
co nd ition ; th e  c o n d it io n s  o f  5 p a tie n ts  can  be  c o n s id e re d  
g o o d '. T h re e  p a tie n ts  d ie d  d u r in g  c o u rse  o f  th e  tre a tm e n t 
and 5 p a tie n ts  o p te d  o u t fro m  th e  s tu d y . W e c o n s id e re d  th e  
cond itions o f  th e  p a tie n ts  as e x c e lle n t, w h e re  th e  p a tie n ts  a re  
leading a lm o s t n o rm a l life  a n d  th e  d is e a se  is a p p a re n tly  in
rem iss io n . G o o d  c o n d itio n  h e re  in d ic a te s  th a t  a lth o u g h  th e  
p a tie n ts  h av e  so m e  a ilm e n ts , th e se  a re  a t p re s e n t n o t life - 
th re a te n in g  a n d  th e ir  c o n d itio n s  a rc  m o re  o r  less s tab le . 
M o re o v e r  it a p p e a rs  th a t th e se  a ilm e n ts  a re  m a in ly  d u e  to  
th e  d a m a g e  a lre a d y  c a u se d  b y  m a lig n a n c y  a n d /o r  b y  th e  
p re v io u s  tre a tm e n t o f  c h e m o - o r  ra d io th e ra p y .
In a d d itio n  to  th e  su m m a ry  o f  th e  re su lts  a s  p re s e n te d  in  
T a b le  1, so m e  c o m m e n ts  on  th e  c o n d itio n  o f  so m e  sp e c if ic  
ca se s  seem s w o rth w h ile .
P a tien t no . 17 ; V e ry  g o o d  r e s p o n s e  w a s  o b s e r v e d  
w ith in  7 d a y s  o f  th e  tre a tm e n t. T h e  
p a tie n t w as a c tiv e  an d  m o b ile  a n d  in 
g e n e ra l ly  g o o d  p h y s ic a l  c o n d it io n . 
H o w e v e r, th e  c o n d it io n  d e te r io ra te d  
su d d e n ly  tw o  w e e k s  b e fo re  d e a th ; d ie d  
S e p te m b e r 2 0 0 0 .
P a tie n t no . 18 : G o o d  p re lim in a ry  re sp o n se , th e re  w as  
a lle v ia tio n  o f  b re a th in g  tro u b le ; b u t th e  
p a t i e n t  d ie d  p r o b a b ly  d u e  to  th e  
p ro g re ss io n  o f  th e  d ise a se .
P a tie n t no. 21 : T h e re  w a s  s ig n if ic a n t  im p ro v e m e n t 
a fte r  o n ly  1 c o u rse  o f  th e  tre a tm e n t, b u t 
th e  p a tie n t o p te d  o u t a f te r  fiv e  c o u rse s  
an d  d ie d  in A u g u s t 2 0 0 0 .
lalilc 1. Characteristics of the patients and outcome of the treatment (for further details see text).
Age/Sex Diagnosis Time of 
detection
Previous treatment received Commencement 




32/M Adenocarcinoma of colon, 
metastasis to liver (both lobes)
October 1999 Surgical resection of tumor, 
palliative treatment suggested
January 2000 Excellent
73/F Acute myeloid leukemia Do Palliative treatment suggested 
due to very poor physical 
condition
Do Do
46/M Non-Hodgkin's lymphoma, 
metastasis to lung and possibly 
to liver (relapsed case)
December 1998 Chemotherapy twice without 
response
February 2000 Do
72/F Mucin-sccreting adenocarcinoma 
of colon, metastasis to liver, 
pericolic lymph nodes and gall 
bladder
December 1999 A portion of the colon and 
gall bladder excised. Palliative 
treatment suggested
Do Do
40/F Adenocarcinoma of ovary 
(relapsed after one year) with 
metastasis to omentum and 
peritoneal seeding
December 1998 Ovaries removed followed by 
chemotherapy. After relapse 
chemotherapy was non- 
responsive
March 2000 Do
40/F Serous cell adcnocardnoma of 
ovary (left), recurrence in right 
ovary during chemotherapy
January 2000 Surgical removal of left ovary, 
chemotherapy non-responsive, 
surgical removal of right ovary
Do Do
62/F Infiltrating duct carcinoma of 
breast with metastasis in 
axillary lymph node and bone 
(stage IIIB)
Do Mastectomy done followed by 
radiation
Aprit 2000 Do
56/F Infiltrating duct carcinoma of 
breast with metastasis in lymph 
node and lung (stage IIIB-IV)
Do Mastectomy done. Patient 
refused chemotherapy
Do Do
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Patient Age/Scx Diagnosis fiine ol 
dclcciion
Previous irciiimcFii received Commencement 




9 36/M Papillary transitional cell
carcinoma. 4th time recurrence
10 54/F Multiple myeloma (relapsed)
osteoporosis
11 61/Nl Colorectal carcinoma
12 35/M Ampullary carcinoma of
liver, metastasis to pancreas 
with billiary obstmetion
13 72/M Hepatocellular carcinoma
14 70/F Adenocarcinoma of colon,
metastasis to liver and 
probably also in bone marrow
15 ^78/M  Squamous cell carcinoma of
tongue (recurrence in Nov 
1999)
16 68/F Non-Hodgkin's lymphoma,
metastasis to lung (small 
cell carcinoma), significant 
pleural cflusion
17. 67/M Renal cell carcinoma (^ p -
tember 1998), metastasis to 
lung and banc ^February 2000)
18 75/M Bronchogenic carcinoma
with massive pleural cfTusion
19 55/F Infiltrating duct carcinoma
with metastasis to breast, 
lung and liver (July 1999) 
ascites in peritonium
20 40/M Infiltrating squamous cell
carcinoma of larynx, 
metastasis to lymph gland
21 SS/M Carcinoma of oesophagus
22 65/F Metastatic adenocarcinoma
of gall-bladder with 
involvement of liver and 
pancreas
23 78/M Squamous cell carcinoma of
cheek (3rd time relapse)
24 50/F Adenocarcinoma of pancrcas-
colangio-carcinonia, 














Surgery' followed by cliemo- April 2000
therapy twice A Her 4th 
recurrence patient refused 
chemotherapy
2nd time chemotherapy did May 2000
not respond
Surgical removal, external Do
colcstomy hag Patient 
iclused chemotherapy due 
to poor physical condition




Palliative treatment suggested May 2000
Do June 2000
Chemotherapy given on first Do
detection, af\cr recurrence only 
palliative treatment suggested 
due to poor physical condition
Patient refused chemotherapy Do
due to poor health
Surgical removal of the kidney March 2000
in 1998 and palliative treatment 
suggested after recurrence
Palliative treatment suggested January 2000
Surgery, radiotherapy and March 2000
chemotherapy done with 
no response
Surgery performed before May 2000
Only palliative treatment April 2000
suggested
Choledochoduodenostomy May 2000
was done, palliative 
treatment suggested
June 2000
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4. Discussion
T he re su lts  o f  th e  p re s e n t s tu d y  a p p e a r  to  b e  v e ry  p ro m is in g . 
B ecause, m a n y  o f  th e  p a tie n ts  w h o  h a d  v o lu n te e re d  fo r th is  
s tudy  h ad  m e ta s ta t ic  c a rc in o m a , re c e iv e d  c o n v e n tio n a l 
trea tm en t se v e ra l tim e s ; h o w e v e r  th e ir  c o n d it io n s  fu r th e r  
d e te rio ra ted . T h e re  w e re  m a n y  re la p se d  c a se s  a lso , w h e re  th e  
p h y sic ian s w h o  h a d  tre a te d  p re v io u s ly  th o u g h t o f  v e ry  p o o r  
p ro g n o sis  w h a t u su a lly  h a p p e n s .
H o w e v e r  it is r e m a rk a b le  to  n o te  th a t o f  th e  19 p a tien ts  
w ho h ad  c o n tin u e d  w ith  th e  p re s e n t tr e a tm e n t, o n ly  3  
patien ts d ie d . T h e  c o n d it io n s  o f  o th e r  p a tie n ts  im p ro v e d  
d ram atica lly .
In th e  p re s e n t c o n te x t , so m e  c o m m e n ts  on  th e  p o ss ib le  
toxic e ffe c t o f  m e th y lg ly o x a l se e m s w o rth w h ile . It h as  b een  
su g g e s te d  fo r  s o m e tim e  b y  s e v e r a l  in v e s t ig a to rs  th a t 
m e th y lg ly o x a l h a s  b o th  in vitro an d  in vivo to x ic  e ffe c ts  
[13 ,14]. H o w e v e r , e a r ly  s tu d ie s  b y  A p p le  an d  G re e n b e rg  an d  
S zen t-G yO rgyi et al h a d  sh o w n  th e  m e th y lg ly o x a l w as  w e ll 
to lera ted  in vivo [ 2 - 5 ] .  M o re o v e r , th e  p re s e n t s tu d y  c le a rly  
indicates th a t in  c o m b in a tio n  w ith  o th e r  p ro te c tiv e  a g e n ts  
m e th y lg ly o x a l h a s  n o  m a jo r  in vivo to x ic  e ffe c t. I f  a t a ll th e re  
is any m in o r  a d v e rs e  e ffe c t, th a t is m o re  th a n  c o m p e n sa te d  
by the a p p a re n t to ta l  c o n tro l o f  m a lig n a n c y .
In se v e ra l p re v io u s  p u b lic a tio n s  fro m  o u r  la b o ra to ry , w e  
had sh o w n  th a t m e th y lg ly o x a l s tro n g ly  in h ib its  th e  e le c tro n  
flow th ro u g h  c o m p le x  1 o f  th e  m ito c h o n d r ia l re sp ira to ry  
chain o f  s p e c if ic a lly  m a lig n a n t c e lls . W e h a d  a lso  sh o w n  th a t 
m e th y lg ly o x a l s p e c if ic a lly  in a c tiv a te s  g ly c e ra ld e h y d e -3 -  
phosphate  d e h y d ro g e n a s , th e  k e y  e n z y m e  o f  th e  g ly c o ly tic  
pathw ay. T h is  is th e  o n ly  e n z y m e  in th e  g ly c o ly tic  p a th w a y  
re s p o n s ib le  f o r  th e  p r o d u c t io n  o f  N A D H  ( r e d u c e d  
n ic o t in a m id e  a d e n in e  d in u c l e o t i d e ) .  T h is  N A D H  is 
su b seq u en tly  o x id iz e d  th ro u g h  c o m p le x  1. A lm o s t 8 5 %  o f  
the A T P  g e n e ra te d  in  th e  c e ll a re  p ro d u c e d  b y  th e  e le c tro n  
flow th ro u g h  c o m p le x  1 o f  th e  m ito c h o n d r ia l re sp ira to ry  
chain by  th e  o x id a tio n  o f  N A D H . D u e  to  th e  in h ib itio n  o f  
com plex 1 a n d  in a c tiv a t io n  o f  th e  e n z y m e  g ly c e ra ld e h y d e -  
3 -ph o sp h ate  d e h y d ro g e n a s e  o f  sp e c if ic a lly  m a lig n a n t ce lls  
by m e th y lg ly o x a l th e s e  c e lls  a re  d e v o id  o f  A T P  an d  h e n c e  
the tu m o ric id a l e f f e c t o f  m e th y lg ly o x a l.
So, it a p p e a rs  th a t  th e  u n d e r ly in g  p r in c ip le  o f  th e  in vitro 
tum oiic ida l e f f e c t o f  m e th y lg ly o x a l a n d  o f  th e  d e s tru c tio n
o f  sp e c if ic a lly  th e  m a lig n a n t ce lls  in  p a tie n ts  is b a s ic a lly  th e  
sam e . T h e  re su lts  o f  th e  a b o v e -m e n tio n e d  s tu d y  a n d  tlie  
p r o p o s e d  m e c h a n is m  o f  th e  t u m o r i c id a l  e f f e c t  o f  
m e th y lg ly o x a l s tro n g ly  su g g e s t th a t th e  p re s e n t fo rm u la tio n  
is  e sse n tia lly  th e  d ru g  o f  c h o ic e  fo r  th e  tre a tm e n t o f  c a n c e r ,« 
a lth o u g h  th e re  is a  v as t sc o p e  fo r im p ro v e m e n t o f  th e  
fo rm u la tio n  an d  a lso  in tre a tm e n t sc h e d u le . M o re o v e r  
ju d ic io u s  m ed ica l su p erv isio n  an d  su p p o rt, an d  p ro p e r  c lin ica l 
m o n ito r in g  o f  th e  p a tie n ts ’ c o n d itio n s  a rc  im |>erative.
W e s in c e re ly  h o p e  th a t re se a rc h e rs  an d  c lin ic ia n s  w ith  
o p en  m in d  w ill im m e d ia te ly  m a k e  a c o n c e rte d  e f fo r t  to  u se  
a n d  to  fu r th e r  im p ro v e  th e  p re se n t fo rm u la tio n  a n d  tre a tm e n t. 
T h en  an d  o n ly  th en , th is  d re a d fu l d ise a se  fro m  w h ic h  
m illio n s  o f  p e o p le  a re  su ffe r in g  a t p re se n t th ro u g h o u t th e  
g lo b e  w ill be  tru ly  c o n tro lled .
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